Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failureNina Worel, Hildegard Greinix, Regina Reisner et al.|Journal of Clinical Apheresis|2016Cited by 36
Ruxolitinib therapy for myelofibrosis in AustriaMaria‐Theresa Krauth, Heinz Gisslinger, Sonja Burgstaller et al.|Wiener klinische Wochenschrift|2018Cited by 6
BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trialFelix Keil, Thomas Pabst, Antonia Müller et al.|EClinicalMedicine|2023Cited by 6
A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma PatientsFelix Keil, Thomas Pabst, Antonia Müller et al.|Blood|2022Cited by 1
BendaEAM Versus BEAM as Conditioning Regimen for ASCT in Patients with Relapsed Lymphoma (BEB): A Multicentre, Randomised, Phase II TrialFelix Keil, Thomas Pabst, Antonia Müller et al.|SSRN Electronic Journal|2023Cited by 0